Healthcare Alliance for Resourceful Medicines Offensive against Neoplasms in HematologY
The HARMONY Alliance is a European Network of excellence that captures, integrates, analyzes and harmonizes Big Data from high-quality multidisciplinary sources for the purpose of acquiring valuable knowledge across the spectrum of blood cancers i.e. hematologic malignancies (HMs).
HARMONY is made up of 53 Partners and 27 Associated Members: 72 participants from 15 European countries and 8 pharmaceutical companies. The highly multidisciplinary project brings together key stakeholders in the clinical, academic, patients, Health Technology Assessment, regulatory, economic, ethical, ICT, and pharmaceutical fields.
The main goal of the HARMONY project is to develop a HM-specific Big Data platform, to enable the rapid definition of promising treatment strategies, and prediction of adverse events likely to be associated with such strategies. This platform represents a tool to determine treatment options for the individual patient, and will take into account demographic differences, genomic information as well as the needs of the individual patient. To improve reliability, and therefore the value of the data, HARMONY will specifically address the need to define standard sets of outcome measures that are relevant to all stakeholders, and that will help monitor treatment.
HARMONY aims to establish a more efficient process of treatment development and regulatory evaluation: this can only be achieved by the concerted action of a multidisciplinary partnership, which includes institutions, industry, hospitals, HTA, payers, and organizations with the required know-how and a proven track-record of excellence.
HARMONY will uniquely enable all key healthcare system stakeholders to assemble, connect, analyze and interpret Big Data, and to define standard sets of HM outcome indicators that are relevant and meaningful to all stakeholders, thus harmonizing a pan-European approach towards the measurement-based decision-making in HMs at all levels of the healthcare system.
HARMONY constitutes a powerful representative European Network of Excellence to address these challenges and thereby improve both the treatment outlook and health-related quality of life (QoL) for patients with HMs.
HARMONY Alliance is funded through the Innovative Medicines Initiative (IMI), Europe's largest public-private initiative aiming to speed up the development of better and safer medicines for patients. HARMONY has received funding from IMI 2 Joint Undertaking and is listed under grant agreement No. 116026. This Joint Undertaking receives support from the European Union’s Horizon 2020 Research and Innovation Programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). IMI supports collaborative research projects and builds networks of industrial and academic experts to boost pharmaceutical innovation in Europe.
HARMONY activities and related tasks officially started in January, 2017 and will be accomplished within 60 months. HARMONY is structured in 8 distinct, highly interconnected work packages (WPs). HARMONY will focus on 7 blood cancers, HMs: Acute lymphoblastic leukemia, Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia, Myelodysplastic Syndromes, Non-Hodgkin’s Lymphoma, Multiple Myeloma and Pediatric Hematologic Malignancies.